According to official information from the Cuban institution, the serum will be assessed at Amedeo Di Savoia University Clinic. It is the first collaboration between an Italian public scientific institution and Finlay Vaccine Center.

The Italian clinic will assess the ability of the antibodies developed in Cuba to neutralize different variants of SARS-CoV-2.

‘Thanks to friendship and collaboration that emerged when Cuban doctors aided Turin region to fight coronavirus, to the assistance by the Agency for Cultural and Economic Exchange with Cuba, to the Sano Giusto e Solidale Network and to the embassies of both countries, an important collaboration began.’

The only vaccine candidate specially designed to re-stimulate immunity previously induced by other anti-Covid-19 vaccines or by natural infection, Soberana Plus has already completed its phase I and II clinical trials in Cuba.

mh/pll/mem / cdg